Common tumor inhibitor drug triggers unfavorable immune effects
Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni, Ph.D., assistant professor ...
Jun 22, 2021
0
14